Based in California with global clientele, we are a boutique consulting company comprised of seasoned US-based and international experts in rare and ultra-rare genetic disorders. We are focused on providing highly-specialized genomic and therapeutic scientific and strategic services to pharmaceuticals, biotechs, molecular diagnostic labs, academics, healthcare systems and non-profit organizations.

We were founded in 2021 by Dr. Qais Abu Ali (MD, FACMG), an American-board certified physician-geneticist and drug developer whose clinical-scientific-executive track record in ultra-rare disorders has culminated in successfully utilizing various therapeutic platforms to develop multiple investigational therapies for patients of all age groups and obtain drug approvals in the US, EU and other regions of the world.